Costs of vision impairment: present and future issues

Author: Keeffe, Jill E

Source: Expert Review of Pharmacoeconomics and Outcomes Research, Volume 7, Number 5, October 2007 , pp. 523-527(5)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

There is no standard method for measuring costs of vision impairment. Examples are given of global estimates and from two industrialized countries, Australia and the USA. The comparisons between these countries illustrate how the differences in healthcare systems influence the contribution of direct and indirect costs to the total. Modeling of costs and outcomes (cost-effectiveness analysis) has illustrated the extraordinary benefit of programs to prevent vision loss and blindness. These data need to be used in advocacy for the funding of national Vision 2020: the Right to Sight programs.

Keywords: blindness; costs; low vision; methodology; vision impairment

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737167.7.5.523

Publication date: 2007-10-01

More about this publication?

Expert Review of Pharmacoeconomics & Outcomes Research provides expert commentary on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites